Search Weight Loss Topics:

Page 20«..10..19202122..3040..»

Home » Hgh » Page 20

Three days after failing a drug test and having his July 9 fight against Jerry Forrest canceled, Jarrell "Big Baby" Miller made his first public comments about the failure, pushing back against the allegations.

"I have never, ever willingly taken a steroid for performance-enhancing purposes," Miller told Fight Network. "Did I take something for healing properties, for injuries? Yes, I have. But to win a fight and during a training camp? No, I have never done that.

"Nobody can be more outraged than me," he said of the allegations. "I'm the one that's lost millions of dollars. I'm the one that's had his career on the line. ... But I have to think about it with a straight mind. I have to figure it out. Sit down with my team. Get everything in order and get everything done in the right way."

Miller stated repeatedly that his team is going through a legal process and that, ultimately, the facts surrounding this situation will be released. He believes he listed the contaminated substance on a form that is submitted to the Voluntary Anti-Doping Association as part of the testing process.

2 Related

The most recent drug test failure is another in a growing line of infractions for Miller. Last year, Miller (23-0-1, 20 KOs) was scheduled to face unified heavyweight titleholder Anthony Joshua at Madison Square Garden in New York, but he lost that opportunity as he tested positive for the banned substance GW1516 with a urine test conducted by the VADA in March 2019. Further tests revealed HGH and IPO. In total, Miller failed three drug tests prior to his scheduled bout with Joshua.

At the time, Miller's request for a boxing license was denied by the New York State Athletic Commission, and he was eventually given a six-month suspension by the WBA. Miller has not fought since. The last time Miller performed in the ring was in November 2018, when he stopped Bogdan Dinu in four rounds.

Miller was also suspended for nine months in 2014 for methylhexaneamine, during his days as a kickboxer.

In January, Miller agreed to a co-promotional deal to fight under the Top Rank banner, and the July 9 fight was to be his debut for the promotion. As he reflected on the current situation, Miller apologized to those who had given him another chance.

"I've done my research and homework to do my best to not make this happen, and all I can do is apologize to Bob Arum, apologize to Jay [Prince]," he said. "But at the same time, I did do my homework. I did put my best foot forward. I did let VADA know of certain circumstances. I did my part as a human being and as a fighter ..."

While the details are sorted out and Miller is now temporarily suspended by the Nevada State Athletic Commission, some have called for the permanent revocation of Miller's boxing license. Miller was adamant that a permanent suspension would be excessive in this case.

"I should not be banned [for life]," he said. "I'm prepared to accept my suspension and be willing to do my monthly testing [during] my suspension, but to be banned for life? You're out of your mind.

"It's sad. I'm angry about it, but like I said, there is an explanation for it, and me and my legal team are working on it."

ESPN's Steve Kim contributed to this report.

Excerpt from:
Jarrell Miller says he has never willingly taken a steroid to enhance performance - ESPN

The Health and Safety Executive (HSE) says it carried out more than 1,000 spot checks in the first three weeks after it resumed inspections.

The safety watchdog restarted proactive inspections of construction and other sites in late May. Figures supplied to Construction News by the body for the three weeks between 26 May to 18 June show that the organisation carried out what it termed spot checks at 1,055 businesses across all sectors.

The organisation defines spot checks to include phone calls as well as site visits. It did not break down the figures between types of sector.

Some 107 firms who were subject to spot checks were subject to follow-ups from inspectors.

A spokesman said: HSE inspectors and local authority inspectors are visiting workplaces across a range of sectors following up reports or concerns about safety in the workplace including over COVID-19 and ensuring compliance. HSE is carrying out proactive checks to ensure that appropriate measures are in place to protect workers from COVID-19.

Putting duty holders on the spot, and checking on how they are managing risks has always been part of our regulatory approach.

The organisation has, however, suspended its release of RIDDOR statistics relating to the coronavirus, in what a spokesman said would be a temporary move while it refines its data collection processes. Up to the beginning of May, the organisation said there had been 198 RIDDOR reports of dangerous occurrences and 71 fatal-disease reports relating to COVID-19 across all industries.

One of the firms subject to an unannounced visit by inspectors was HGH Groundworks and Civil Engineering at a site where the firm is the largest subcontractor. Its head of safety, health, environment and quality Martin McCabe told Construction News that the inspector carried out a routine-style visit with added questions and checks on its processes for mitigating coronavirus.

It was an overall holistic visit where they were looking at everything. As a groundworks company they were pretty interested about the plant side of things and any issues [there could have been].

They asked about our processes, what we were doing about COVID-19 and how its managed.

The inspector found no issues on the site, McCabe said.

Last month Mike Clancy, general secretary of the Prospect union, which represents HSE inspectors, warned that the organisation would not be able to carry out spot checks with much frequency after it restarted work. The common understanding of what the HSE would do is much at odds with what it can do, due to its level of resourcing, he told CN.

See the article here:
HSE 'putting firms on the spot' over COVID-19 - Construction News

Alexion Pharma Receives European Approval for Ultomiris

Alexion Pharmaceuticals (ALXN) announced that its lead drug candidate Ultomiris has been approved by the European Commission. Ultomiris may now be used for treating adults and children with atypical hemolytic uremic syndrome in Europe. The drug candidate is the first and only long-acting C5 complement inhibitor that needs to be administered every eight weeks.

The European Commission based its data on two global, single arm studies of the drug candidate. One of these studies was conducted in adults while the other was conducted in children. Both the trials are still operational. The interim analysis involved 56 out of 58 complement inhibitor treatment-nave adults and 18 out of 21 complement inhibitor treatment-nave children. For the initial 26-week treatment periods, 54 percent of adults and 77.8 percent (interim data) of children showed Complete TMA Response.

In the 52-week follow-up period, 4 more adult patients and 3 pediatric patients demonstrated a Complete TMA Response that was validated after the 26-week Initial Evaluation Period. This additional data takes the overall Complete TMA Response of 61 percent in adults and 94 percent in children as shown in interim data.

The drug is expected to create a niche for itself in the market with its convenient dosage regimen of eight weeks. John Orloff, M.D., of Alexion said, Treatment with ULTOMIRIS offers convenient eight-week dosing, which we believe is preferred by patients because it provides them with greater flexibility and improved quality of life, while also reducing the burden on healthcare systems that currently face significant strain in many countries. Atypical HUS is an ultra-rare disease which impacts vital organs such as kidneys by damaging walls of blood vessels.

The company has established a Risk Management Plan for ULTOMIRIS for minimizing the risk of side effects for patients. The most frequently observed adverse reactions related to the drug were nausea, upper respiratory tract infection and headache, among others. ULTOMIRIS is known to cause meningococcal infections, however, aHUS studies did not report any such incident.

ULTOMIRIS was approved by the FDA in 2019 for treating aHUS in adult and pediatric patients of one month of age and older. The drug is also approved in the United States and Japan for treating adult patients suffering from paroxysmal nocturnal hemoglobinuria. In Europe, the drug is authorized for treating patients with PNH with hemolysis with clinical symptoms indicative of high disease activity. The companys application for marketing authorization as a treatment for aHUS is currently under review in Japan.

ULTOMIRIS works by controlling the C5 protein in the terminal complement cascade. The treatment is designed to be administered intravenously every eight weeks or every four weeks for pediatric patients less than 20 kg, following a loading dose.

Alexion is a biopharmaceutical firm and focuses on complement biology and inhibition. The company has two approved complement inhibitors and two enzyme replacement therapies in its portfolio. It also has robust development pipeline with a number of prospective therapies in advanced trial stages. The company seeks to work on developing novel molecules and their impact on core therapeutic areas such neurology and nephrology.

Intercept Pharmaceuticals Inc. (ICPT) reported that it has received a Complete Response Letter from the FDA with regard to its Fibrosis drug. The letter indicates that agency has found the predicted benefits of the drug candidate to be uncertain. The FDA has recommended the company to submit post-interim analysis efficacy and safety data. The FDA stated that it felt that the modest fibrosis effect was not clearly predictive of clinical efficacy,

Intercept had earlier indicated that it expected the review may take longer than the previously announced PDUFA goal date as the agency had postponed a tentatively planned advisory committee meeting. Mark Pruzanski, M.D.,CEO of Intercept said, At no point during the review did the FDA communicate that OCA was not approvable on an accelerated basis, and we strongly believe that the totality of data submitted to date both meet the requirements of the Agencys own guidance and clearly support the positive benefit-risk profile of OCA. The FDA has recommended the company to continue the long-term outcome phase of its trial.

The NDA submission for obeticholic acid is the first for NASH. The application was backed by the data collated from 35 clinical trials. OCA is the only investigational NASH drug to demonstrate replicable ability to overturn or stabilize liver fibrosis in patients with advanced fibrosis due to NASH. The FDA has asked Intercept to submit additional data from its ongoing REGENERATE study to support its potential accelerated approval pathway.

There is no approved therapy for treating NASH fibrosis yet. OCA has been given Breakthrough Therapy designation by the FDA. The OCA is already approved by the FDA for treating primary biliary cholangitis.

Ascendis Pharma A/S (ASND) announced that it has submitted a Biologics License Application to the FDA seeking label expansion for TransCon. The company is looking to add the treatment of pediatric growth hormone deficiency to its label. Currently, there is no approved long-acting growth hormone treatment available in the United States or Europe.

TransCon hGH is a long-acting once-weekly prodrug of somatropin and aims to work on the same mode of action as daily daily hGH therapies. The drug candidate provides the therapeutic benefits by releasing the same growth hormone molecule, somatropin. Jan Mikkelsen, CEO of Ascendis said, We believe the TransCon technology has the potential to address major unmet medical needs and we look forward to continuing the late stage clinical development of our other endocrinology rare disease product candidates, TransCon PTH and TransCon CNP, as well as filing an Investigational New Drug application for our first oncology product candidate later this year.

The company plans to file a Marketing Authorization Application for the drug candidate in Europe during the third quarter. The drug candidate has orphan designation for GHD in both the United States and Europe. Ascendis plans to begin a new Phase 3 trial with TransCon hGH in pediatric GHD in Japan. The trial will likely be initiated in the fourth quarter. Another Phase 3 trial is currently underway in Greater China. Ascendis is collaborating with VISEN Pharmaceuticals for this purpose.

TransCon denotes Transient Conjugation and is a proprietary technology platform for producing more efficient therapies. The three main components of a TransCon molecule are an unmodified parent drug, an inert carrier to protect it and a liker to temporarily bind the two.

Ascendis Pharma has strong development pipeline with three independent endocrinology rare disease product candidates. The company is now looking to expand its focus on oncological segment.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read more:
Alexion's European Approval And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

This report also covers the impact of COVID-19 on the global market. The pandemic caused by Coronavirus (COVID-19) has affected every aspect of life globally, including the business sector. This has brought along several changes in market conditions.

The Infrared Search and Track IRST Systems Market report considers the major factors accountable for driving the growth of the Infrared Search and Track IRST Systems Industry, in addition to the key hindrances and challenges. In the initial segment of the report, the market definition, market overview, product description, product scope, product characterization, and product specification has been discussed. The information presented in this report provides an overview of the latest trends and development plans, patterns, and policies observed in the global market. Moreover, the study offers an analysis of the latest events such as the technological advancements and the product launches and their consequences on the global Infrared Search and Track IRST Systems market. The global market also comprises the data accumulated from numerous primary and secondary sources.

To get SAMPLE of the report, please click:https://www.reportsmonitor.com/request_sample/978121

TheMajorPlayers Covered in this Report: Leonardo S.p.A, Thales Group, Rheinmetall AG, Lockheed Martin Corporation, Northrop Grumman Corporation, Aselsan A.S., HGH Systmes Infrarouges SAS, Safran S.A., Tonbo Imaging Private Limited, Hughes Network Systems LLC, etc. & More.

Based on the Type:Airborne PlatformNaval PlatformLand PlatformOthers

Based on the Application:Defense SectorLaw EnforcementHomeland SecurityOthers

Results of the recent scientific undertakings towards the development of new Infrared Search and Track IRST Systems products have been studied. Nevertheless, the factors affecting the leading industry players to adopt synthetic sourcing of the market products have also been studied in this statistical surveying report. The conclusions provided in this report are of great value for the leading industry players. Every organization partaking in the global production of the Infrared Search and Track IRST Systems market products have been mentioned in this report, in order to study the insights on cost-effective manufacturing methods, competitive landscape, and new avenues for applications.

Global Infrared Search and Track IRST SystemsMarket: Regional SegmentationFor further clarification, analysts have also segmented the market on the basis of geography. This type of segmentation allows the readers to understand the volatile political scenario in varying geographies and their impact on the global Infrared Search and Track IRST Systemsmarket. On the basis of geography, the global market for Infrared Search and Track IRST Systemshas been segmented into:

North America(United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Grab Your Report at an Impressive Discount @https://www.reportsmonitor.com/check_discount/978121

Report Methodology:

The information enclosed in this report is based upon both primary and secondary research methodologies.

Primary research methodology includes the interaction with service providers, suppliers, and industry professionals. Secondary research methodology includes a meticulous search of pertinent publications like company annual reports, financial reports, and exclusive databases.

Key questions answered in this report:1. What will the market size be in 2026 and what will the growth rate be?2. What are the key market trends?3. What is driving this market?4. What are the challenges to market growth?5. Who are the key vendors in this market space?6. What are the market opportunities and threats faced by the key vendors?7. What are the strengths and weaknesses of the key vendors?

For More Details On this Report:https://www.reportsmonitor.com/report/978121/Infrared-Search-and-Track-IRST-Systems-Market

Any special requirements about this report, please let us know and we can provide custom report.

Contact UsJay MatthewsDirect: +1 513 549 5911 (U.S.)+44 203 318 2846 (U.K.)Email: sales@reportsmonitor.com

View post:
Global Infrared Search and Track IRST Systems Market Size |Incredible Possibilities and Growth Analysis and Forecast To 2026 | Leonardo SpA, Thales...

What is Norditropin, prefilled pen injection and what is it used for?

Therapeutic class: Somatropin and Somatropin Agonists

Norditropin HGH Injections

Norditropin HGH pens contain the human growth hormone analog somatropin, which is identical to the growth hormone naturally produced by the human body. Children need the growth hormone to promote their growth, but adults also need it for their general health.

In children, Norditropin is used to treat growth disorders:

In adults, Norditropin is used as a growth hormone replacement when its production has been reduced from childhood or stopped in adulthood due to a tumor, tumor treatment, or pituitary gland disease. If treated for HGH deficiency in your childhood, the persistence of this deficiency will be reassessed when growth is complete. If the growth hormone deficiency is confirmed, further treatment is necessary. Somatropin can also be prescribed to those experiencing wasting caused by HIV.

Read Also: HGH Benefits: What to Expect From Using Human Growth Hormone

Never use Norditropin prefilled pen injections:

Warnings and precautions

Talk to your doctor or pharmacist before using Norditropin:

Tell your doctor or pharmacist if you are using or have recently used any of the following medications:

Read Also: Anti-Aging: HGH Can Reduce Biological Age by One Year and a Half Study Shows

Products containing somatropin are not recommended for women of childbearing age who do not use contraception.

Norditropin NordiFlex has no effect on the ability to drive vehicles and operate machinery.

Always use this medicine exactly as directed by your physician. Consult your doctor or pharmacist if you are unsure.

In children, the dose depends on weight and body surface area. After childhood, the dose depends on height, weight, sex, and sensitivity to growth hormone and is adjusted until the optimal dose is reached.

When using Norditropin 5 mg/1.5 mL, prefilled pen injection solution

Inject your daily dose under the skin every evening just before bedtime.

How to use Norditropin pen?

Do not share on your Norditropin pen with other people.

If you have accidentally used more Norditropin than you needed Consult your doctor or pharmacist immediately!

If you have injected too much somatropin, talk to your doctor. Prolonged somatropin overdose may cause abnormal growth and thickening of the facial features (Acromegaly).

If you forgot to use Norditropin:

Take the next usual dose at the usual time. Do not take a double dose to make up for the lost dose.

When discontinuing Norditropin injections do not stop taking Norditropin without first consulting your doctor.

If you have further questions about the use of this medicine, ask your doctor or pharmacist for more information.

Like all medicines, this medicine may have side effects. However, these side effects do not always occur in everyone.

Adverse reactions in children and adults (frequency not known) :

If you experience any of these effects, consult a doctor as soon as possible. Stop taking Norditropin until your doctor tells you to start taking it again.

The formation of antibodies that act directly against somatropin has rarely been observed during treatment with Norditropin.

High concentrations of liver enzymes have been reported.

Leukemia and recurrent brain tumors have also been reported in patients treated with somatropin (the active ingredient of Norditropin NordiFlex), although there is no evidence that somatropin is responsible.

If you think you have any of these conditions, talk to your doctor.

Additional side effects in children:

Unusual (may affect up to 1 in 100 children):

Rare (may affect up to 1 in 1,000 children):

Rare cases of hip and knee pain and limping have been reported in children taking Norditropin. These symptoms may be related to a disorder of the femur (Legg-Calve-Perthes disease) or slippage of the tip of the femur in relation to the cartilage (epiphysiolysis of the femoral head) and may not be due to Norditropin.

Read Also: Do HGH Supplements Like Genf20 Plus, Growth Factor Plus, GenfX, Hypergh 14X, HGH X2 and Provacyl Work?

In children with Turner syndrome, clinical studies have observed some cases of increased growth of hands and feet in relation to height.

A clinical study in children with Turner syndrome showed that high doses of Norditropin may increase the risk of ear infections.

If any of these side effects affect you significantly, or if you notice any side effects not listed in this guide, you should talk to your doctor or pharmacist as the dose may be reduced.

Additional adverse reactions in adults

Very common (may affect more than 1 in 10 adults):

Unusual (may affect up to 1 in 100 adults):

If you experience any side effects, talk to your doctor or pharmacist. This also applies to any side effects not mentioned in this article. You can also report adverse reactions directly to the FDA.

By reporting adverse reactions, it helps to provide more information on the safety of the medicine.

Read Also: Increasing Height: Can HGH Help You Grow Taller?

Keep the medicine out of sight and out of the reach of children.

Do not use this medicine after the expiry date shown on the container.

Store unused Norditropin in a refrigerator (between 2C and 8C) away from light. Do not freeze or expose to heat.

After starting to use Norditropin store the opened pen in a refrigerator (between 2C and 8C) for up to 4 weeks or store at room temperature (not above 25C) for up to 3 weeks

Do not continue to use a Norditropin pen that has been frozen or exposed to excessive temperatures.

Do not use Norditropin Pen if the growth hormone solution inside is opaque or discolored.

Always store Norditropin without a needle.

Always keep the cap of the Norditropin Pen closed when not in use.

Always use a new needle for each injection.

Do not dispose of drugs in the sewerage system or with household waste. Ask your pharmacist to dispose of medicines that you no longer use. This will help to protect the environment.

Read Also: Growing Taller as an Adult: Is It Possible?

Norditropin is presented as a clear, colorless injectable HGH solution in a pre-filled 1.5 mL multi-dose disposable pen.

Norditropin is available in three strengths:

5 mg/1.5 mL, 10 mg/1.5 mL and 15 mg/1.5 mL (3.3 mg/mL, 6.7 mg/mL and 10 mg/mL respectively).

https://www.norditropin.com/

Continued here:
Norditropin: The facts about this Prescription HGH Brand - Gilmore Health News

The 2019 Norwegian based company is leaving the nest and taking the world by storm.

The creators, five Medical Doctors, spearheaded by the Co.Founder and Executive Chairman Mehdi Ettehadulhagh M.D., who is also currently an award winning innovation designer. Together with Co.Founders Nayyer Ettehadulhagh and Sina Ettehadulhagh, are putting the Entrepreneur in Entrepreneurship with their minimalistically daring designs, cutting edge textile engineering and innovations, enough to make the wheel yesterdays news.

This product (HTM1) is turning heads, already winning the Invention of the Year award few months after its release during the Medical Congress of 2019, held by the UPCAM!

With their first batch of gear going from exclusive sales in Scandinavia to shipping worldwide this year (2020), this is the type of innovation we expect from the VOT brand startup. So before melting into a pool of fandom like the witch from OZ, let us recap what this HTM1 really does!

Occluding Venous Blood-flow

Apparently getting in shape is not as simple as cucumber-water and protein-bars! Starting to workout three weeks before summer isnt going to cut it.

Or is it?

The science says; when we workout, blood flows through our bodies, and the blood that is tainted with lactic acid and growth hormones actually stimulate muscle growth! When the concentration of these hormones are high, the muscles react accordingly and grow. Mostly with exercise above 80% of our max effort.

Theres a catch, normally, the amount of growth hormones (HGH) and lactic acid stimulating the muscle is reduced in concentration due to blood-flow. (Think the amount of fish in a river, diluted throughout) Thats where the HTM1 comes in.

By slightly reducing the blood-flow out of the muscle by a few percent, the lactic acid concentration builds up around the muscle, (Think putting a dam on that same river, thus increasing the concentration of fish without increasing the amount of fish.) causing a significant increase in the concentration as well as the anabolic effect on muscle cells, the bonus? you only need to lift 15-20% of your 1RM to gain the same result as your 80-100% 5RM, yeah crazy, we know!

In other words, you now CAN start working out three weeks before summer!Watch a HTM1 transformation below:

https://votwear.com/blogs/news/173-day-occlusion-training-wear-transformation

Whats next for the SmartWear company; VOTwear?

While there are oceans of research available on their website, the brand seeks to do more than help you build big biceps quicker and easier. The goal of VOTwear is not only to provide innovative SmartWear, but also a format of expressing important values for individuals on a journey of seeking excellence, and redefining what we thought was written in stone.

Physiotherapy, de-loading, muscle-building, fat-loss, injury prevention, cardiac strength, these are few of many benefits BFRwear (blood flow restriction) has shown to provide, especially when combined with heavy weight training, does the HTM1 capacity seem to explode.

A young brand, but rooted in age old values of giving your purest and best- Less is more atvotwear.com

About VOTWEAR

VOTwear is a Norwegian SmartWear company, currently unveiling the worlds first venous occlusion training wear.

Read the original:
VOTwear- Pushing The Boundaries Of Training Wear. - PRUnderground

Gov. Kate Brown and the Oregon Health Authority approved Marion County to enter Phase 2 of its reopening roadmap, beginning June 19

Gov. Kate Brown and the Oregon Health Authority approved Marion County to enter Phase 2 reopening, beginning Friday, June 19, county officials announced June 17.

"This important milestone comes at a critical time of need as families struggle with unemployment, businesses work hard to recover, and farmers begin their harvests," said Marion County Commissioner Kevin Cameron. "We're thrilled to enter Phase 2 and get public life in Marion County moving again."

Marion County analyst Chad Ball noted that Phase 2 allows swimming pools, bowling alleys, movie theaters, and arcades to reopen. Bars and restaurants are able to expand hours of operation to stay open until midnight, and social, civic and faith-based gatherings can meet in larger groups.

Some recreational sports can resume, including training activities within college athletic programs.

But Phase 2 also retains several physical distancing and sanitation measures for businesses and other activities to help limit the spread of the coronavirus as people become more active in the community.

The announcement comes as the governor's office also outlined some stricter measures for some counties, including requiring masks to be worn at all public indoor areas, such as grocery stores.

The governor put a hiatus on counties applying for Phase 1 and Phase 2 reopening last week as the number of daily positive and presumptive COVID-19 cases were spiking. The state saw a record 278 cases reported June 16, including 119 in eastern Oregon's Union County where an outbreak was connected to a La Grande-area church.

"I instituted the statewide pause because of the rising number of cases in both rural and urban communities," Brown said. "I did this to give public health experts time to assess what factors are driving the spread of the virus and make adjustments to our reopening strategy.

"Since then, the Oregon Health Authority has continued to analyze data in the state, including the source of the growth in new cases, hospitalizations, results of contact tracing and other metrics."

Brown said after consultations with health officials and civic leaders, Marion will join Multnomah, Washington, Clackamas, Hood River, Polk and Lincoln counties as jurisdictions where masks will be required at all indoor public spaces, beginning June 24. This step is taken as Marion, Polk and Hood River counties move into Phase 2, and Multnomah County moves to Phase 1.

"All three (Phase 2) counties have implemented timely follow-up on cases in the past week," Brown said. "While Multnomah County has seen an increase in new cases recently, the county has not experienced an uptrend in new hospital admissions, and overall hospitalizations remain well within capacity."

Brown said her office will take a more regional approach with regard to reopening decisions in the future.

"I will be grouping several counties together as regional units for future reopening decisions. This will apply to the tricounty area Multnomah, Washington, and Clackamas counties will be treated as a single unit in future reopening decisions," Brown said. "And Marion and Polk counties, which each include parts of the city of Salem, will also be treated as a unit going forward.

"Both of these regions include a highly connected urban area, making it difficult to monitor the disease based solely on the contours of county jurisdictional lines."

Ball noted that Marion County's roadmap for reopening was developed in collaboration with county health experts, other local leaders and regional public health partners.

"We're proud to see that our county has successfully slowed the spread of COVID-19 to the point where we can confidently move into Phase 2," said Marion County Commission Chair Colm Willis on June 17. "Today's success is a testament to the hard work and resiliency of the people of Marion County."

County officials continue to stress that anyone who feels sick should remain at home, regardless of the reopening. Hgh-risk individuals who are over 65 years old or suffering chronic illnesses also should continue to remain home as much as possible.

"We encourage all individuals to continue to follow physical distancing guidelines. All businesses, organizations and activities that choose to reopen should follow state guidelines, many of which are available by specific sector and type of activity," Ball said, urging residents to adhere to the face-covering recommendations and rules as well.

The governor said with the metro counties in Phase 1 and mid-Willamette Valley counties transitioning to Phase 2 reopening, the coming weeks will be crucial ones in the battle to stem the spread of COVID-19.

"The next few weeks will be difficult, and we will be monitoring the data regularly. We are much better prepared than we were in early March; we have increased PPE, much more widespread testing, and many more contact tracers," Brown said.

"However, if hospitalizations spike too rapidly, if the capacity of our health care system is threatened, we will be forced to revert to stricter rules.

"Our entire ability to reopen and stay open is dependent on whether each of us follows basic health and safety protections," she added. "Stay home if you feel sick, wear a face covering, keep six feet of distance, avoid crowds, and wash your hands regularly. We truly are all in this together."

You count on us to stay informed and we depend on you to fund our efforts.Quality local journalism takes time and money. Please support us to protect the future of community journalism.

Go here to read the rest:
Phase 2 reopening OK'd in Marion County; masks to be required - Pamplin Media Group

In 2014, shortly after a TKO loss to Michael Bisping in Macau, Cung Le tested positive for elevated levels of Human Growth Hormone (HGH). The UFC promptly handed Le a nine-month suspension, which was later elevated to a twelve-month term.

Fight fans were quick to pile-on and vilify Lebut things were not as cut-and-dry as they seemed.

In the weeks following Les failed drug test, it became clear that his result was due to a handful of errors and oversights on the part of the UFC and its partners.

While operating in Macau, which does not have its own athletic commission, the UFC operated as its own governing body, and hired a local testing facility to undertake anti-doping measures. As it turned out, this facility was not WADA-approved, and made a number of key errors in its testing proceduresmost notably testing Le after a gruelling fight, at which point HGH levels would naturally be higher.

They said I took HGH, Lee recounted on the latest episode of BJPENN.com Radio. Dr. [Don] Caitlin, an Olympic testing specialist, didnt stick up for me because he knew me or liked me. He stuck up for his 10 years of research saying that UFCs claims against me for taking HGH were wrong.

If youre doing testing, you have to test when [the test subject] is fasted and when their resting heart rate is normal or when they just woke up, Le continued. They literally tested me and Michael right after the fight. I was clean of everything else. I even took another test and put it out there and compared the two tests. Of course my HGH level was spiked because I literally got blood drawn out of me right after the fight. They pulled me back to the bathroom when I was all bloody, I actually had just lost the fight. I went four and a half rounds against Michael Bisping. Of course my levels are going to be elevated. Im bleeding out of my face, the bone underneath my eye was broken. So my body was trying to heal itself right then and there, of course my HGH levels going to be through the roof. And then for them to throw me under the bus

Cung Le continued, explaining that his and Bispings tests were destroyed immediately after the fact, which also damaged the credibility of the claims against him.

I asked them, hey, wheres Michaels test? [I said] I want to do the blood test again, lets do it again. Theyre like, Oh, its been destroyed. So right there I knew if youre not on their team, if youre not with them, youre against them.

Just prior to his fight with Bisping, Le had been offered a new eight-fight deal with the UFC. He says he declined to sign it because he wasnt able to connect with his lawyer, but the UFC encouraged him to sign anyway, evidently upset by his reluctance.

Right before I left, they wanted me to sign another eight-fight deal, Le said. I wouldve signed it. I was already thinking of moving down in weight, because all these guys [at middleweight] are so huge.

I mentioned that to Dana[ white], he added. I didnt sign my deal memo right then and there, because my lawyer was out of town. They wanted me to sign it right then and there, like literally the day before I flew out to Vietnam to finish up my training camp so I could acclimate to the time in China.

Les failed drug test and resulting suspension were ultimately rescinded for precisely the reason he describes above. After this fiasco, however, he decided against signing a new deal with the UFC, and instead requested his release from the promotion.

He has not fought since.

Today, Cung Le is involved in an anti-trust lawsuit against the UFC. Hes also working as a brand ambassador for a new combat sports promotion called EKIC, which places significant importance on treating fighters properly.

Give EKIC a follow on social media! Twitter / Facebook / InstagramCheck out their site here EKICLLC.COM

View original post here:
Cung Le looks back on drug-testing fiasco with UFC: They threw me under the bus - BJPENN.COM

Market Data Analyticspublished the market research study on the globalKiln Shell Scanner market. The report on the Kiln Shell Scanner market incorporates all the minute details about the market. As the world is right now dealing with the COVID-19 situation, all the markets in every region has been hit hard within these few months. The governments and the market players are planning out different strategies in order to revive the economic crisis of the regions and the countries.

Request Free Sample Copy of Market Research Report@https://www.marketdataanalytics.biz/global-kiln-shell-scanner-market-report-2020-industry-analysis-15412.html#request-sample

Chapter 1: Market Overview

The chapter deals with the Kiln Shell Scanner market definition or the overview for better understanding the market scope and the target audience of the market.

Chapter 2: Research Methodologies/ Tools

The research analysts have made use of various methodologies, tools, and researches in order to obtain the Kiln Shell Scanner market data. Primary and secondary researches were conducted to obtain the current market numerical and information.

Chapter 3: Kiln Shell Scanner Market DROC

In this chapter, there are various sub-sections and each deal with the market dynamics. The flow of the sections is: Kiln Shell Scanner market growth factors and limitations. In the later section, the Kiln Shell Scanner market opportunities and challenges. All the points mentioned within the report are updated based on the COVID-19 situation.

Read Full Research Report::https://www.marketdataanalytics.biz/global-kiln-shell-scanner-market-report-2020-industry-analysis-15412.html

Chapter 4: Market Segmentation

The Kiln Shell Scanner market is segmented into{Standard Scanner, Stereo Scanner};{On-Line Measurement, Preventative Maintenance}. Each of the market segments are explained in detail by the research analysts. Both qualitative and quantitative information about the Kiln Shell Scanner market segments are included. The information is depicted in the form of tables and figures for better understanding.

Chapter 5: Kiln Shell Scanner Market Regional Segmentation

The Kiln Shell Scanner markets regional presence is segregated into five main regions North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. Along with these main regions country-wise data is also provided for the Kiln Shell Scanner market.

Chapter 6: Company Profiles

All the market players functioning in the Kiln Shell Scanner market are profiled in detail in the report. The list includes all the major players along with the distributors, retailers, and suppliers information.Details of the market playersRaytek, ThyssenKrupp, FLIR Systems, FLSmidth, Thermoteknix, HGH, Siemens, Syn-Fab, Baoyi Mech & Elec Instrumentare also incorporated in the Kiln Shell Scanner market report.

Chapter 7: Conclusion and Observations

Last chapter of the report includes comments and observations by the research analysts and the market experts for the Kiln Shell Scanner market.

Inquire for further detailed information of Kiln Shell Scanner Market Report at:https://www.marketdataanalytics.biz/global-kiln-shell-scanner-market-report-2020-industry-analysis-15412.html#inquiry-for-buying

Read more:
Global Kiln Shell Scanner Market with (COVID-19) Impact Analysis | likewise Industry is Booming Globaly with Top Players Raytek, ThyssenKrupp, FLIR...

Global Thermal Scanners Market 2020features key points about market share, new developments, and product analysis, market players, analysis of opportunities. According to the globalThermal Scannersmarket report, major advancements and capacity development are driving the worldwide market. Made by using integrated approaches, this report is divided by company, by country, and by application/types for the competitive landscape analysis. The markets boom and developments are studied and an in-depth review is been given. It displays trends, drivers, and challenges of the market. Market share analysis and key trend analysis are the major accomplishing factors of this market document.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/418012/request-sample

Scope of GlobalThermal ScannersMarket:

The report is confident in providing an inclusive point of view on the market to those who are involved in the globalThermal Scannersindustry or interested to enter. The report gives you knowledge about segmented by applications, product types, and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

Furthermore, the survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report. The competitive landscape of the globalThermal Scannersmarket consists of several global and regional players.

REQUEST FOR CUSTMIZATION:https://www.fiormarkets.com/enquiry/request-customization/418012

Some are the key players taken under coverage for this study are:Opgal, Seek Thermal, Leonardo S.p.A., Axis Communications AB, Tonbo Imaging, C-THERMAL, Infratec GmbH, Terabee, AMETEK Land, HGH Infrared Systems, Fluke Corporation, VUMII Imaging, Optotherm, Inc., L3harris Technologies, Inc., FLIR Systems, Inc., Thermoteknix Systems Ltd., Xenics, Testo SE & Co. KGaA, Cox, HGH Infrared Systems, and 3M Scott among others.

By regions, this report splits the globalThermal Scannersmarket into several key regions, with sales, revenue, price, and gross margin market share of top players in these regions, like:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/thermal-scanners-market-by-type-portable-fixed-technology-418012.html

Key Benefits of Purchasing This Report:

The study provides an in-depth analysis of the globalThermal Scannersmarket with current and future trends. Current and future trends are outlined to determine the overall attractiveness of profitable trends to gain a stronger foothold in the market. Drivers and opportunities are evaluated to highlight the top factors responsible for market growth. Value chain analysis in the report gives a clear understating of the roles of stakeholders involved in the value chain. The report also incorporates information such as economic scenarios, benefits, limits, trends, market growth rates, figures, and SWOT analysis.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Originally posted here:
Global Thermal Scanners Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2027 - Bulletin Line

Page 20«..10..19202122..3040..»

Home » Hgh » Page 20